Decreased native renal T1 up to one week after gadobutrol administration in healthy volunteers

Gadolinium‐based contrast agents (GBCAs) are widely used in MRI, despite safety concerns regarding deposition in brain and other organs. In animal studies gadolinium was detected for weeks after administration in the kidneys, but this has not yet been demonstrated in humans.

[1]  B. Maes,et al.  Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. , 2020, Journal of magnetic resonance imaging : JMRI.

[2]  S. Trattnig,et al.  Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T. , 2019, Investigative radiology.

[3]  M. Prince,et al.  A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. , 2019, Radiology.

[4]  A. Stanescu,et al.  Gadolinium-based contrast agents — review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients , 2019, Pediatric Radiology.

[5]  R. Lenkinski,et al.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. , 2018, Radiology.

[6]  E. Vink,et al.  Modified dixon‐based renal dynamic contrast‐enhanced MRI facilitates automated registration and perfusion analysis , 2017, Magnetic resonance in medicine.

[7]  M. Prince,et al.  Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis. , 2017, Radiology.

[8]  M. Kirchin,et al.  Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats , 2017, Journal of magnetic resonance imaging : JMRI.

[9]  D. Kallmes,et al.  Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates. , 2017, Radiology.

[10]  Cyprian Olchowy,et al.  The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review , 2017, PloS one.

[11]  E. Lancelot.  Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion , 2016, Investigative radiology.

[12]  A. Dohan,et al.  Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study , 2016, Journal of magnetic resonance imaging : JMRI.

[13]  Stefan Klein,et al.  PCA-based groupwise image registration for quantitative MRI , 2016, Medical Image Anal..

[14]  K. Maravilla,et al.  High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function , 2016, Investigative radiology.

[15]  David F Kallmes,et al.  Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. , 2015, Radiology.

[16]  Yu-Chung N. Cheng,et al.  Introductory Signal Acquisition Methods: Free Induction Decay, Spin Echoes, Inversion Recovery, and Spectroscopy , 2014 .

[17]  Yu-Chung N. Cheng,et al.  Signal, Contrast, and Noise , 2014 .

[18]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[19]  J. Gauvrit,et al.  Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents: The Prospective Fibrose Nephrogénique Systémique Study , 2014, Investigative radiology.

[20]  Stefan Klein,et al.  Fast parallel image registration on CPU and GPU for diagnostic classification of Alzheimer's disease , 2013, Front. Neuroinform..

[21]  Josef Coresh,et al.  Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  S. Aime,et al.  Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.

[23]  D. Armbruster,et al.  Limit of blank, limit of detection and limit of quantitation. , 2008, The Clinical biochemist. Reviews.

[24]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[25]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  W. Gibby,et al.  Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.

[27]  Peter Jezzard,et al.  Rapid T1 mapping using multislice echo planar imaging , 2001, Magnetic resonance in medicine.

[28]  H. Weinmann,et al.  Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy Volunteers , 1994, Investigative radiology.

[29]  P. Mansfield,et al.  High‐speed multislice T1 mapping using inversion‐recovery echo‐planar imaging , 1990, Magnetic resonance in medicine.

[30]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[31]  Max A. Viergever,et al.  elastix: A Toolbox for Intensity-Based Medical Image Registration , 2010, IEEE Transactions on Medical Imaging.

[32]  D. Solís.  US Food and Drug Administration , 2010 .